array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Tekla Life Sciences Investors" ["slug"]=> string(38) "30be8-us-tekla-life-sciences-investors" ["logo"]=> NULL ["description"]=> string(523) "Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL." ["address_street"]=> string(17) "2 Liberty Sq FL 9" ["address_place"]=> string(6) "Boston" ["address_region"]=> string(13) "Massachusetts" ["founding_date"]=> string(10) "2000-01-26" ["website_domain"]=> string(12) "teklacap.com" ["website_url"]=> string(24) "https://www.teklacap.com" ["industry_codes"]=> array(1) { [0]=> string(39) "Management Investment Offices, Open-End" } ["employee_count"]=> int(7) ["article_count"]=> int(78) } ["articles"]=> array(3) { [0]=> array(7) { ["title_en"]=> string(72) "Tekla Capital Management LLC Announces Closing of Transaction With abrdn" ["snippet_en"]=> string(300) "BOSTON–(BUSINESS WIRE)–HQH, HQL, THQ, THW Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manager to four NYSE listed healthcare and biotech thematic" ["url"]=> string(101) "https://www.fintechnews.org/tekla-capital-management-llc-announces-closing-of-transaction-with-abrdn/" ["image_url"]=> NULL ["source"]=> string(15) "fintechnews.org" ["publication_date"]=> string(10) "2023-10-29" ["categories"]=> array(5) { [0]=> string(25) "Business Model Resilience" [1]=> string(11) "Acquisition" [2]=> string(20) "Business Development" [3]=> string(10) "Divestment" [4]=> string(22) "Business Restructuring" } } [1]=> array(7) { ["title_en"]=> string(72) "Tekla Capital Management LLC Announces Closing of Transaction With abrdn" ["snippet_en"]=> string(297) "Tekla Capital Management LLC announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manager to four NYSE listed healthcare and biotech thematic closed-end funds, totaling$ 2.8 bn in assets under" ["url"]=> string(120) "https://www.nasdaq.com/press-release/tekla-capital-management-llc-announces-closing-of-transaction-with-abrdn-2023-10-27" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-06-30" ["categories"]=> array(5) { [0]=> string(25) "Business Model Resilience" [1]=> string(11) "Acquisition" [2]=> string(20) "Business Development" [3]=> string(10) "Divestment" [4]=> string(22) "Business Restructuring" } } [2]=> array(7) { ["title_en"]=> string(72) "Tekla Capital Management LLC Announces Closing of Transaction With abrdn" ["snippet_en"]=> string(99) "Tekla Capital Management LLC( Tekla) announced today that it has completed the sale of its advisory" ["url"]=> string(134) "https://www.morningstar.com/news/business-wire/20231027387331/tekla-capital-management-llc-announces-closing-of-transaction-with-abrdn" ["image_url"]=> NULL ["source"]=> string(15) "morningstar.com" ["publication_date"]=> NULL ["categories"]=> array(1) { [0]=> string(10) "Divestment" } } } ["category_annotations"]=> array(22) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(16) } [1]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(6) } [2]=> array(2) { ["name"]=> string(10) "Tax Havens" ["count"]=> int(6) } [3]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(5) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(4) } [5]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(4) } [6]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(4) } [7]=> array(2) { ["name"]=> string(16) "Share Repurchase" ["count"]=> int(4) } [8]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(3) } [9]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [11]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(2) } [12]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [13]=> array(2) { ["name"]=> string(22) "Business Restructuring" ["count"]=> int(2) } [14]=> array(2) { ["name"]=> string(20) "Corporate Governance" ["count"]=> int(2) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(23) "Supply Chain Management" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(19) "Investment Requests" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(1) } } } 30be8-us-tekla-life-sciences-investors